Across GLP-1 and incretin-based therapies, we are seeing outcomes beyond the scale: - fewer major cardiovascular events - kidney protection - improvements in conditions tightly linked to cardiometabolic dysfunction, including sleep apnea biology We should stop treating obesity as a cosmetic problem and start treating it like the systemic disease driver it is, across joints, heart, kidneys, and sleep
Liraglutide 3 mg/day resulted in a median weight loss of 9.7%, whereas WR was 1.8% in the placebo group at the end of 56 weeks [48]
tirzepatide: Exploring weight loss potential Retatrutide is getting a lot of attention for its early results, but tirzepatide is still considered to be the GLP-1 medication associated with the most weight loss currently
Not only may there be a new pharmacotherapy for AUD, but the success of these drugs forces a reconceptualization of addiction itself
I sought extra training in womens hormones, understanding how critical hormonal health is to vitality, well-being, and quality of life